A Two-part, Phase I/IIA dose Excalation Study to Define the Safety, Tolerability, and optimal Dose of candidate GBM vaccine VBI-1901 with Subsequent Extension of Optimal Dose in Recurrent GBM Subjects

Protocol: 
AAAR5300
Phase: 
I/II

A Two-part, Phase I/IIA dose Excalation Study to Define the Safety, Tolerability, and optimal Dose of candidate GBM vaccine VBI-1901 with Subsequent Extension of Optimal Dose in Recurrent GBM Subjects

The purpose of this study is to test the safety of a new vaccine, VBI-1901,
and to know more about it's ability to boost the response of the immune
system against Cytomegalovirus.

The reason for testing this vaccine in people with a brain tumor is that it
might one day be used to boost the ability of the immune system to fight a
certain type of brain tumor. This type of treatment for brain tumors is
called immunotherapy.

Are you Eligible? (Inclusion Criteria)

Participants must:
1. Be 18 - 70 years of age
2. Have histologically confirmed WHO grade IV glioblastoma
3. Have unequivocal evidence of a tumor recurrence (any number of
recurrences) or progression after an initial treatment regimen (prior to
enrollment on this study)
4. Have recovered from the effects of surgery

Specialty Area(s)

Immunotherapy

Trial Location

Herbert Irving Comprehensive Cancer Center
161 Fort Washington Ave.
Herbert Irving Pavilion
New York, NY 10032
United States